Built and now lead the safety epidemiology group to support the COVID-19 and other vaccine programs. Our team leads a number of studies and works cross-functionally to develop evidence that supports the post-licensure environment of the COVID-19 vaccine program.

Vaccine and Drug Development Programs- Post-licensure safety / effectiveness studies to support regulatory and commercial objectives- Develop and execute epidemiology strategies to support regulatory approvals (FDA / EMA)- Extensive experience with data science and large datasets- Develop and deliver evidence to support product value - Design and conduct global primary data collection studies to communicate disease burden - Develop quality of life assessments and Patient Reported Outcome instruments- Validation of measurements- Manage a group of professional scientists- Drug development: HIV, HCV, CMV, C. difficile, antibiotics, antifungals- Vaccine development: Rotavirus, HPV, HIV, Pertussis

Lead epidemiologist for several vaccine programs (e.g., Rotavirus, HPV, HIV and others). Developed and successfully led large research programs to demonstrate unmet medical need, suport clinical development and FDA / EMA post-marketing commitments.

Lead epidemiologist for the rotavirus vaccine program. Planned and executed multiple global studies that supported successful licensure and launch of the RotaTeq vaccine. Initiated and successfully delivered post-marketing studies to demonstrate the safety and effectiveness of the rotavirus vaccine in multiple regions. Conducted large scale demonstration project in Nicaragua to accelerate vaccine access in less developed regions.